Modus Therapeutics presents final data from its Phase 1b LPS-provocation study with sevuparin at the annual ISICIP symposium in Barcelona
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
STOCKHOLM, SWEDEN – October 5, 2023: Modus Therapeutics AB (“Modus”), a company developing innovative treatments for patients with major unmet medical needs in acute and advanced care, presents results from the final data analysis of their Phase 1b LPS challenge study in healthy volunteers. In this study, the effect of Modus’ proprietary substance sevuparin was studied against the background of an acutely provoked systemic inflammation. The study will be presented as part of the "Best poster presentation" session at the 27th International Symposium on Infections in the Critically Ill Patient (ISICIP), October 5-6 in Barcelona, Spain.
The poster entitled "The effects of sevuparin in induced systemic inflammation- A randomized, placebo-controlled LPS-challenge study" will be presented orally by Modus’ CEO, John Öhd on behalf of all co-authors. The presentation includes final analyses of the effects of sevuparin on certain types of white blood cells and clinical signs following LPS challenge (induced endotoxemia) in healthy volunteers. In accordance with the preliminary Topline analysis communicated in a press release earlier this year, the efficacy data from this study together with the favorable safety profile of sevuparin support the continued development of the substance as a treatment for acute systemic inflammation disorders such as sepsis and endotoxemia.
The study was a randomized, double-blind and placebo-controlled study in healthy volunteers. The data to be presented at this year's ISICIP includes both a systemic and a local (skin) LPS challenge and study endpoints that capture the clinical and biomarker-related effects of three different doses of sevuparin compared to placebo under induced systemic and local inflammatory conditions. At the same time, the safety and tolerability profile of sevuparin was observed under these conditions.
John Öhd, Chief Executive Officer of Modus Therapeutics commented: “Representing Modus and our partners, I am honored that our work was selected for the best poster session in this year's ISICIP, as it is a prestigious symposium with a long tradition that attracts the international expertise in the field of acute and intensive care-related infectious manifestations. The positive clinical results with sevuparin that we report in this analysis of the final data are completely in line with the preliminary Topline data described briefly in a company press release earlier this year. It is exciting that our previous preclinical studies in the sepsis field demonstrated that sevuparin primarily exerts its positive effects on leukocyte and pulmonary disease biology, which is in accord with the clinical data now at hand. We are convinced that the experiences gained from this study has the potential to contribute significantly to the design of our future planned studies in patients with sepsis and other types of acute systemic inflammation.”
In the design and delivery of this Phase 1b study, Modus collaborated with The Centre for Human Drug Research (CHDR) in Leiden, The Netherlands, an independent Contract Research Organisation (CRO), which specializes in advanced early clinical drug research based on its leading expertise in inflammation models.
The ISICIP symposium homepage and program is here: https://isicip23.com/index.php